PL2211892T3 - Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczne - Google Patents
Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczneInfo
- Publication number
- PL2211892T3 PL2211892T3 PL08844568T PL08844568T PL2211892T3 PL 2211892 T3 PL2211892 T3 PL 2211892T3 PL 08844568 T PL08844568 T PL 08844568T PL 08844568 T PL08844568 T PL 08844568T PL 2211892 T3 PL2211892 T3 PL 2211892T3
- Authority
- PL
- Poland
- Prior art keywords
- basic protein
- myelin basic
- compositions
- protein peptides
- medical uses
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 title abstract 2
- 102000047918 Myelin Basic Human genes 0.000 title abstract 2
- 101710107068 Myelin basic protein Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Confectionery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0721430A GB0721430D0 (en) | 2007-10-31 | 2007-10-31 | Composition |
| GB0800962A GB0800962D0 (en) | 2008-01-18 | 2008-01-18 | Conposition |
| PCT/GB2008/003673 WO2009056833A2 (en) | 2007-10-31 | 2008-10-30 | Composition |
| EP08844568A EP2211892B1 (en) | 2007-10-31 | 2008-10-30 | Compositions comprising myelin basic protein peptides and medical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2211892T3 true PL2211892T3 (pl) | 2012-01-31 |
Family
ID=40591554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08844568T PL2211892T3 (pl) | 2007-10-31 | 2008-10-30 | Kompozycje zawierające peptydy zasadowych białek mieliny i ich zastosowanie medyczne |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8623827B2 (enExample) |
| EP (1) | EP2211892B1 (enExample) |
| JP (1) | JP5361895B2 (enExample) |
| KR (1) | KR101570383B1 (enExample) |
| CN (1) | CN101848725B (enExample) |
| AT (1) | ATE518546T1 (enExample) |
| AU (1) | AU2008320657B2 (enExample) |
| BR (1) | BRPI0818302B1 (enExample) |
| CA (1) | CA2703170C (enExample) |
| CY (1) | CY1112620T1 (enExample) |
| DK (1) | DK2211892T3 (enExample) |
| EA (1) | EA017999B1 (enExample) |
| EC (1) | ECSP10010211A (enExample) |
| HR (1) | HRP20110724T1 (enExample) |
| IL (1) | IL204662A (enExample) |
| MX (1) | MX2010004698A (enExample) |
| MY (1) | MY158800A (enExample) |
| NZ (1) | NZ583924A (enExample) |
| PL (1) | PL2211892T3 (enExample) |
| PT (1) | PT2211892E (enExample) |
| SI (1) | SI2211892T1 (enExample) |
| WO (1) | WO2009056833A2 (enExample) |
| ZA (1) | ZA201001748B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1311542T1 (sl) | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| US8623827B2 (en) | 2007-10-31 | 2014-01-07 | Apitope Technology (Bristol) Limited | Myelin basic protein peptide composition |
| WO2011046462A1 (en) * | 2009-10-12 | 2011-04-21 | Angport Limited | Composition for treatment of multiple sclerosis |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| GB201603582D0 (en) * | 2016-03-01 | 2016-04-13 | Apitope Int Nv | Peptides |
| ES2996275T3 (en) * | 2017-01-04 | 2025-02-12 | Worg Pharmaceuticals Zhejiang Co Ltd | Therapeutic method using dose escalation protocol for tolerogenic peptides |
| GB201700095D0 (en) * | 2017-01-04 | 2017-02-22 | Apitope Int Nv | Composition |
| US20210093695A1 (en) * | 2017-08-14 | 2021-04-01 | Apitope Technology (Bristol) Limited | Method |
| JP2024518277A (ja) | 2021-04-16 | 2024-05-01 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 免疫寛容の維持を追跡する方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| SI1311542T1 (sl) * | 2000-08-21 | 2009-02-28 | Apitope Technology Bristol Ltd | Tolerogenski peptidi |
| US20040096456A1 (en) | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| US8623827B2 (en) | 2007-10-31 | 2014-01-07 | Apitope Technology (Bristol) Limited | Myelin basic protein peptide composition |
-
2008
- 2008-10-30 US US12/740,976 patent/US8623827B2/en active Active
- 2008-10-30 BR BRPI0818302-3A patent/BRPI0818302B1/pt active IP Right Grant
- 2008-10-30 DK DK08844568.9T patent/DK2211892T3/da active
- 2008-10-30 EA EA201070541A patent/EA017999B1/ru not_active IP Right Cessation
- 2008-10-30 EP EP08844568A patent/EP2211892B1/en active Active
- 2008-10-30 AU AU2008320657A patent/AU2008320657B2/en active Active
- 2008-10-30 CN CN2008801138365A patent/CN101848725B/zh active Active
- 2008-10-30 SI SI200830411T patent/SI2211892T1/sl unknown
- 2008-10-30 NZ NZ583924A patent/NZ583924A/en unknown
- 2008-10-30 WO PCT/GB2008/003673 patent/WO2009056833A2/en not_active Ceased
- 2008-10-30 CA CA2703170A patent/CA2703170C/en active Active
- 2008-10-30 PT PT08844568T patent/PT2211892E/pt unknown
- 2008-10-30 JP JP2010530555A patent/JP5361895B2/ja active Active
- 2008-10-30 HR HR20110724T patent/HRP20110724T1/hr unknown
- 2008-10-30 MY MYPI2010001917A patent/MY158800A/en unknown
- 2008-10-30 AT AT08844568T patent/ATE518546T1/de active
- 2008-10-30 KR KR1020107005853A patent/KR101570383B1/ko active Active
- 2008-10-30 MX MX2010004698A patent/MX2010004698A/es active IP Right Grant
- 2008-10-30 PL PL08844568T patent/PL2211892T3/pl unknown
-
2010
- 2010-03-11 ZA ZA2010/01748A patent/ZA201001748B/en unknown
- 2010-03-22 IL IL204662A patent/IL204662A/en active IP Right Grant
- 2010-05-28 EC EC2010010211A patent/ECSP10010211A/es unknown
-
2011
- 2011-10-25 CY CY20111101006T patent/CY1112620T1/el unknown
-
2013
- 2013-12-06 US US14/099,463 patent/US9381234B2/en active Active
-
2016
- 2016-06-03 US US15/173,018 patent/US9775880B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2211892T1 (sl) | Sestavki, ki obsegajo peptide mielinskega bazičnega proteina in njihove medicinske uporabe | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
| EA201490644A1 (ru) | Терапевтические пептиды | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| EA201001883A1 (ru) | Мутанты fgf21 и их применение | |
| EA201270528A1 (ru) | Композиции цитокинов семейства il-17 и их применение | |
| EA201001322A1 (ru) | Вакцины против хламидиоза | |
| MX2015011199A (es) | Agentes terapéuticos de csf1. | |
| IN2012DN02589A (enExample) | ||
| WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
| MX2009009200A (es) | Tratamiento de enfermedades caracterizadas por la inflamacion. | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| MX2011011768A (es) | Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos. | |
| MX2009004862A (es) | Estabilizacion de vacunas por liofilizacion. | |
| PH12017501473A1 (en) | Novel proteins specific for pyoverdine and pyochelin | |
| MX2010005589A (es) | Composicion para el cuidado personal. | |
| WO2010064012A3 (en) | Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 ) | |
| WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
| WO2012090207A3 (en) | Par1 and par2 c-tail peptides and peptide mimetics | |
| WO2010041827A3 (en) | NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME | |
| GB0818080D0 (en) | Immunogenic peptides | |
| GB0423126D0 (en) | Protein | |
| MX2009002717A (es) | Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas. | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |